Show Summary Details
Page of

HIV-1 and Tat Neuropathogenesis and Therapeutic Targets 

HIV-1 and Tat Neuropathogenesis and Therapeutic Targets
Chapter:
HIV-1 and Tat Neuropathogenesis and Therapeutic Targets
Author(s):

Wenxue Li

, Guanhan Li

, Joseph Steiner

, and Avindra Nath

DOI:
10.1093/med/9780195399349.003.0019
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 17 June 2019

The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the neuropathogenesis of HIV infection. This is the earliest protein to be produced by the proviral DNA in the infected cell. The protein not only drives the production and replication of the virus but is also actively released from the cell and then interacts with cell surface receptors of other uninfected cells in the brain leading to cellular dysfunction. It may also be taken up by these cells and can then activate a number of host genes. The Tat protein is highly potent and has the unique ability to travel along neuronal pathways. It can also easily cross the blood brain barrier. Importantly, its production is not impacted by the use of antiretroviral drugs once the proviral DNA has been formed. This chapter reviews the pleomorphic actions of Tat protein in relation to its effects on the nervous system.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.